USA flag logo/image

An Official Website of the United States Government

A2A ADENOSINE AGONIST ADJUNCT FOR SYSTEMIC ANTHRAX

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
60498
Program Year/Program:
2002 / STTR
Agency Tracking Number:
AI053042
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ADENOSINE THERAPEUTICS, LLC
310 FOURTH STREET NE SUITE 201 CHARLOTTESVILLE, VA 22902
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: A2A ADENOSINE AGONIST ADJUNCT FOR SYSTEMIC ANTHRAX
Agency: HHS
Contract: 1R41AI053042-01
Award Amount: $198,360.00
 

Abstract:

DESCRIPTION (provided by applicant): This project develops A2A adenosine receptor (A2AAR) agonists as adjuncts to antibiotics for the treatment of anthrax septicemia. It responds to the urgent need for better treatment of highly lethal infections by this bioterrorism/biowarfare agent. Phase I has two aims, pharmaceutical development and documentation of efficacy in clinically relevant settings. The goal of Aim I is to identify one lead and two to three backup compounds for development. It applies USP criteria to the screening of the company library of 50 proprietary A2AAR agonists for pharmaceutically relevant factors such as in vitro efficacy, solubility, stability to heat, light and pH, followed by secondary screens to document physical characteristics such as pKa, hydrophobicity and affinity for plasma proteins. The goal of Aim 2 is to demonstrate preliminary efficacy. It develops a mouse model of anthrax toxin sepsis by: (1) dose-ranging studies on anthrax lethal toxin (LT); (2) dose-ranging studies of A2AAR agonist protection against LT sepsis; (3) studies of the effect of delay in administration of A2AAR agonist on protection against LT sepsis, and (4) documentation that the A2AAR specifically mediates the protective effect of these agonists. Attaining both aims will argue for continuing on to Phase II for additional assessments of efficacy as well as of pharmacokinetics and metabolism.

Principal Investigator:

W. M. Scheld
4349245241
WMS@VIRGINIA.EDU

Business Contact:

Robert Capon
4342209400
RSCAPON@AOL.COM
Small Business Information at Submission:

ADENOSINE THERAPEUTICS, LLC
ADENOSINE THERAPEUTICS, LLC 300 PRESTON AVE, 5TH FL CHARLOTTESVILLE, VA 22902

EIN/Tax ID: 541932209
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF VIRGINIA
UVA
CHARLOTTESVILLE, VA 24615
RI Type: Nonprofit college or university